Tradestie Institutional Equity Comparison Engine

CING vs RLMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RLMD Overall Edge

RLMD Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Options & Structure while CING counters with relative strength in Momentum & Technical. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RLMD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CING N/M vs RLMD N/M Fwd P/E
Growth & Margin Winner RLMD
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CING
1Y +36.4% vs -22.9% ยท 52W Pos 18% vs 1%
Options & Structure Winner RLMD
BREAKDOWN (16th %ile IV) vs BREAKDOWN (36th %ile IV)
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
1M Return +9.17%
1Y Return +36.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
RLMD NASDAQ
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.04
-15.65% 1D
Market Cap $449.2M
1M Return -3.64%
1Y Return -22.91%
Forward P/E N/M
Unified AI Score
39.0 / 100 SELL
Tech 15.0 Fund 38.0 Flow 68.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CING +36.39% RLMD -22.91% Spread: +59.3 pp (CING Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CING TTM Op. Margin: 0.0% RLMD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs RLMD. Trailing 12-month operating profitability (CING 0.0% vs RLMD 0.0%) and valuation multiples (CING N/M vs RLMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CING (2) vs RLMD (3)
Institutional Metric CING RLMD Criterion Row Winner
Market Capitalization Scale $62.5M $449.2M Larger Scale RLMD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -198.7% -64.7% Higher ROE RLMD
52-Week Range Position Momentum 18% ($3โ€“$12) 1% ($3โ€“$8) Stronger Trend CING
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 117% Vol 1.66ฮฒ ยท 106% Vol Lower Realized Risk RLMD
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 39.0 / 100 (SELL) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CING vs RLMD Buy Guide
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RLMD BREAKDOWN
135d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RLMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CING nor RLMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.